Also a recent study including 33 GCs showed that a tumor immune microenvironment dominated by IFN-γ and T-cell receptor (TCR) signaling was significantly associated with clinical benefit from Pembrolizumab [19]. This evidence concerns the gene IFNG and neoplasm.